Skip to main content
Caplight Logo









Borealis Biosciences

Borealis Biosciences

Private
VancouverHealthcare & Life Scienceshttps://www.borealisbio.com/

Last Round

Series A

Extension

Dec 19, 2024

Total Funding Raised

$210M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Borealis Biosciences is a biotechnology company that develops next-generation xRNA-based medicines for kidney diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticskidney diseasenephrologydrug discoverybiotech startupRNA medicinetranslational biologybuild-to-buytherapeutic developmentbiopharmadrug pipelinestealth biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Borealis Biosciences Comparables

Compare Borealis Biosciences with similar companies based on industry and business-model similarity.

Borealis Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Judo Bio
84%
Purespring Therapeutics
83%
Zeal Therapeutics, Inc.
82%

Borealis Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 19, 2024
Series AAug 22, 2024

Key People

Founding team and executive leadership

Christian Hordo

Chief Executive Officer

Executive Team

Borealis Biosciences Investors

Notable investors and investment history

Borealis Biosciences investors
InvestorRounds
Westlake Village BioPartnersSeries A, Series A Extension
Versant VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 35% to 2.2K.

  • Aug 22, 2024

    $180M round led by Novartis and Westlake Village BioPartners.

Borealis Biosciences Filings

Explore SEC and related filing metadata, where available.

Borealis Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Borealis Biosciences's valuation, stock price, and market status.

Is Borealis Biosciences a public or private company?

Borealis Biosciences is a private company.

What is the current stock price of Borealis Biosciences?

Borealis Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is Borealis Biosciences worth (valuation)?

Valuation information for Borealis Biosciences is not publicly available.

Can I buy Borealis Biosciences stock?

Borealis Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Borealis Biosciences's last funding round?

Borealis Biosciences's most recent funding round was Series A Extension on December 19, 2024.

Who are the main investors in Borealis Biosciences?

Key investors in Borealis Biosciences include Westlake Village Biopartners.

Will Borealis Biosciences IPO soon?

No public IPO plans have been announced for Borealis Biosciences.

How can I track Borealis Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Borealis Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersVancouver
Employee Range49
Year Founded2024
Last FundingDec 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?